Clinical Trial Update: Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial updating the combination of cetuximab with NK immunotherapy for recurrent non-small cell lung cancer (Phase 1/Phase 2) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• NK immunotherapy (natural killer cell-based immunotherapy)

Snippet

Sponsor: Fuda Cancer Hospital, Guangzhou | Conditions: Recurrent Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED